OBJECTIVES: To evaluate the impact of certolizumab pegol (CZP) monotherapy on household work and daily activities in RA patients over 2 years. METHODS: Patients in the FAST4WARD Phase III trial were randomised to CZP 400mg administered every 4 weeks (Q4W) or placebo for 24 weeks. Those who completed or withdrew at/after Week 12 were eligible to enter an open-label extension (OLE) study of CZP 400mg Q4W. This analysis focuses on CZP completers who entered the OLE study and had 2 years (100 weeks) of CZP exposure from baseline (BL). Household productivity and impact on family/social/leisure activities were assessed using the validated Work Productivity Survey (WPS-RA).  Analyses were conducted on observed data. FAST4WARD:NCT00548834; OLE:NCT00160693. RESULTS:  Sixty-nine CZP completers entered the OLE. At BL: mean disease duration: 9.5 years; mean HAQ-DI: 1.42; mean DAS28-3(CRP): 5.76. Burden of RA on household productivity at BL was substantial: mean 10.1 household work days missed/month, mean 12.1 household work days with reduced productivity/month, mean 5 days missed/month of family/social/leisure activities. At Week 100, compared with BL, patients receiving CZP monotherapy reported on average fewer household work days missed per month (1.0 vs 10.1), fewer days with reduced productivity in the home (1.1 vs 12.1), reduced interference of RA on household productivity (2.0 vs 5.8 on a 0–10 scale), fewer missed days of family/social/leisure activities (0.3 vs 5.0). Improvements were seen as early as Week 4 and were sustained until Week 100. Over 12, 52 and 100 weeks, mean annualised cumulative gains from BL were 20.5, 108.4 and 199.3 household work days, respectively, 25.1, 136.0 and 244.9 more productive days within the household, and 11.9, 57.7 and 107.2 days gained of family/social/leisure activities. CONCLUSIONS: CZP 400mg Q4W monotherapy provides sustained improvement in productivity within the home and in RA patients’ abilities to engage in family/social/leisure activities.